Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Epicardial Substrate Ablation in Symptomatic Brugada Syndrome Patients: An Updated Systematic Review and Single-arm Meta-analysis.
Heart Rhythm
January 2025
Dante Pazzanese Institute of Cardiology, Department of Electrophysiology, São Paulo, Brazil.
Background: Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist. In this setting, epicardial substrate ablation has emerged as a promising alternative for symptomatic patients.
View Article and Find Full Text PDFArtemisinin-Quinidine Combination for Suppressing Ventricular Tachyarrhythmia in an Ex Vivo Model of Brugada Syndrome.
J Korean Med Sci
January 2025
Division of Cardiology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Background: The ionic mechanism underlying Brugada syndrome (BrS) arises from an imbalance in transient outward current flow between the epicardium and endocardium. Previous studies report that artemisinin, originally derived from a Chinese herb for antimalarial use, inhibits the Ito current in canines. In a prior study, we showed the antiarrhythmic effects of artemisinin in BrS wedge preparation models.
View Article and Find Full Text PDFAdvances and Challenges in the Management of Brugada Syndrome: A Comprehensive Review.
Cureus
June 2024
Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA.
Article Synopsis
- Brugada syndrome (BrS) is an inherited heart condition that leads to abnormal heart rhythms and an increased risk of sudden cardiac death, primarily caused by mutations in the SCN5A gene.
- Diagnosis can be tricky due to its hidden ECG signs and symptoms that resemble other heart disorders, mostly affecting young, healthy males.
- Treatment mainly involves managing symptoms and preventing sudden death, primarily through implantable cardioverter-defibrillators (ICDs), with recent advancements in catheter ablation and specific medications like quinidine showing promise despite challenges in long-term management and availability.
Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment.
Clin Drug Investig
July 2024
NextGen Precision Health, University of Missouri, 1030 Hitt St., Columbia, MO, 65211, USA.
Article Synopsis
- * PB-TUDCA, one of these treatments, has shown promise in addressing various biological issues related to ALS in clinical trials, particularly in the Phase 2 CENTAUR trial, which indicated improvements in patient outcomes.
- * However, the more recent Phase 3 PHOENIX trial presented contrasting results, showing no significant benefits, leading to the decision to withdraw marketing authorizations for PB-TUDCA from FDA and Health Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!